Loading
Prostatype Genomics BTU Stock: price and insider trades · Sweden
SE·Mcap SEK 16.3M
Prostatype Genomics BTU: what insiders have been doing
Only a handful of insider records exist for Prostatype Genomics BTU, the last one from 5 August 2026, too few to describe a trend. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
as of FY 2025FY ended December 2025 · cache
SEK 0.11
Analyst consensus
Income statement
RevenueSEK 594k
Gross profitSEK 594k100% margin
EBITDA-SEK 40.7M-6852% margin
Net income-SEK 44.5M-7492.1% margin
Valuation
P/Book0.9x
Beta1.40
Balance sheet & cash
Market capSEK 16.3M
Total debtSEK 5.3M
Free Cash Flow-SEK 37.2M
Debt / Equity20%
Profitability & ownership
ROE-176.2%
ROA-55.9%
% insiders35.0%
% institutions4.2%
Last declaration on 5 August 2026
Declarations1 total
334,000 shares@ SEK 0.801.67% mcap100.0% of flowBTU (betald tecknad unit)FI:csv-a14b7c27005bee164503
1 of 1 declaration
About Prostatype Genomics BTU
Prostatype Genomics BTU is a company focused on developing genomic tests for prostate cancer. It is listed on the XSTO market.
